Blood Derivatives

PSC Category 6507-P for Blood Derivatives encompasses medical products and biological substances derived from human blood. This category specifically covers specialized pharmaceutical and medical reagents that are processed from blood components, including plasma-derived treatments, coagulation factor concentrates, and immunoglobulin preparations. These products are critical for medical treatments involving immune deficiencies, hemophilia, and other blood-related medical conditions. The category represents a highly specialized segment of medical supply procurement focused on advanced therapeutic blood-based products.

Recent federal contract awards for blood derivatives demonstrate significant investment in medical research and clinical treatment capabilities. Contract values typically range between $250,000 and $5 million, with durations spanning 12-36 months. Primary funding agencies include the Department of Defense, Department of Veterans Affairs, and National Institutes of Health. Contracts are frequently awarded to specialized biotechnology firms and medical supply manufacturers with advanced blood processing capabilities. Predominant contract mechanisms include small business set-asides and competitive negotiated procurements, with performance locations concentrated in major metropolitan areas with advanced medical research infrastructure.

No specific federal contract opportunities were provided within the submitted materials for PSC Category 6507. Without additional context or source data, a comprehensive description of current solicitations cannot be generated.